Panbela Receives Approvals To Open Trial Sites In Spain, France And Italy For ASPIRE Trial Studying Ivospemin In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Panbela Receives Approvals To Open Trial Sites In Spain, France And Italy For ASPIRE Trial Studying Ivospemin In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced Regulatory approval for the opening of trial sites in Spain, France and Italy for Panbela's clinical trial in the first-line treatment of metastatic pancreatic cancer. ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Detailed information on the trial can be located at
With approximately 95 sites planned throughout the United States, Europe, Australia, and South Korea, we are continuing to focus on site initiation and enrollment in order to ultimately deliver a more effective treatment for pancreatic cancer, a deadly disease with few treatment options. Site initiation can now accelerate, and we are pleased with the current momentum of the ASPIRE trial. We expect that a significant number of global sites will be open by year-end with the full complement of sites open by the first quarter 2023. "We're excited to have these recent approvals as we move forward towards the interim analysis which is expected to be completed in early 2024," commented Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela.
Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced Regulatory approval for the opening of trial sites in Spain, France and Italy for Panbela's clinical trial in the first-line treatment of metastatic pancreatic cancer. ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Detailed information on the trial can be located at
潘貝拉治療學公司。(NASDAQ: PBLA) 是一家臨床階段公司,開發用於治療有緊急未滿足醫療需求的患者的破壞性療法。今天宣布監管局批准在西班牙、法國和意大利開設 Panbela 在轉移性胰腺癌的一線臨床試驗中進行臨床試驗。ASPIRE 是一項全球隨機、雙盲安慰劑對照臨床試驗,用於評估 Ivospemin 與吉西他濱和 NAB-紫杉醇結合治療轉移性胰腺腺癌患者。有關試用的詳細信息,請參閱
With approximately 95 sites planned throughout the United States, Europe, Australia, and South Korea, we are continuing to focus on site initiation and enrollment in order to ultimately deliver a more effective treatment for pancreatic cancer, a deadly disease with few treatment options. Site initiation can now accelerate, and we are pleased with the current momentum of the ASPIRE trial. We expect that a significant number of global sites will be open by year-end with the full complement of sites open by the first quarter 2023. "We're excited to have these recent approvals as we move forward towards the interim analysis which is expected to be completed in early 2024," commented Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela.
在美國、歐洲、澳洲和韓國規劃了大約 95 個站點,我們將繼續專注於場地的啟動和註冊,以最終為胰腺癌提供更有效的治療方法,這是一種幾乎沒有治療選擇的致命疾病。網站啟動現在可以加速,我們對 ASPIRE 試驗的當前勢頭感到滿意。我們預計到年底將有大量全球網站開放,並在 2023 年第一季開放完整的網站。潘貝拉總裁兼首席執行官珍妮弗 ·K· 辛普森博士,MSN,CRNP 表示:「我們很高興能夠獲得這些最近的批准,因為我們向前邁進,該中期分析預計將於 2024 年初完成。」
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧